All In Biotech

Drug Trial Radar · NCT07443059

A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants

A Phase I Clinical Study to Evaluate the Pharmacokinetic Characteristics and Safety of Single-dose of Zovaglutide (ZT002 Injection) in Participants With Different Degrees of Renal Insufficiency and Matched Participants With Normal Renal Function

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Dec 3, 2026

Study completion Mar 19, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal insufficiency and matched participants with normal renal function.

Conditions

  • Overweight , Obesity

Interventions

  • ZovaglutideDrug

    Receive a single dose , SC

  • ZovaglutideDrug

    Receive a single dose , SC

  • ZovaglutideDrug

    Receive a single dose , SC

  • ZovaglutideDrug

    Receive a single dose , SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Tlast (AUC0-t).Time frame: Start of Treatment up to Day 50
  2. Maximum Concentration of ZT002 (Cmax)Time frame: Start of Treatment up to Day 50
  3. Area Under the Concentration Versus Time Curve (AUC) of ZT002 From Time Zero to Infinity (AUC0-∞)Time frame: Start of Treatment up to Day 50
  4. Time to maximum concentration (Tmax)Time frame: From baseline to Day 50
  5. Apparent terminal half-life (t1/2)Time frame: From baseline to Day 50
  6. Apparent clearance (CL/F)Time frame: From baseline to Day 50
  7. Incidence and severity of adverse eventsTime frame: Screening period up to Day 50

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Affiliated Hospital Of Shandong First Medical Unversity

    Jinan, Shandong, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.